Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 635 results for "erbitux"

New treatment combination benefited patients with lung cancer ...

A combination of the EGFR-targeted anticancer therapeutics afatinib (Gilotrif) and cetuximab (Erbitux) yielded clinical responses in 29 percent of patients who had lung cancer harbouring epidermal growth factor receptor (EGFR) mutations that had ... Ecancer Medicalscience, 1 day ago
New Treatment Combination Benefits Patients With EGFR Inhibitors Advance for Respiratory Care & Sleep Medicine, 18 hours ago

4 images for erbitux

Pharma Letter, 4 weeks ago
OncLive, 1 month ago
Scottrade, 1 month ago
OncLive, 1 month ago
Scottrade

Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux (CHIME Trial)

"The commencement of this clinical trial achieves another milestone in the clinical development of HA-Irinotecan as this study will be the first use of a HyACT drug within an antibody-containing regimen, which is the current and future standard of ...
 Noodls1 month ago ALCHEMIA : Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)  4 Traders1 month ago Research and Markets: Antibodies in Oncology Drug Pipeline Analysis 2014: 313 Companies Plus Partners Developing 671 Antibody Drugs in 1619 Developmental Projects  Morningstar.com2 months ago Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?  FirstWord Pharma2 weeks ago
[x]  
Pharma Letter

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows30-06-2014

Merck Serono, the biotech subsidiary of Germany's Merck KGaA (MRK: DE), has released positive new clinical trial results comparing its cancer drug Erbitux (cetuximab) with Swiss drug major Roche's (ROG: SIX) blockbuster Avastin (bevacizumab). ...
 Pharma Letter4 weeks ago From biopsies to blood-based testing  Drug Discovery News3 weeks ago Merck to Collaborate with Sysmex Inostics on a Blood-Based RAS Biomarker Test  Individual.com1 month ago Merck and Sysmex collaborate to develop biomarker test for colorectal cancer  PredictWallStreet1 month ago
[x]  

ESMO: Erbitux No Help in Esophageal Ca (CME/CE)

Gastroenterology Published: Jul 2, 2014 | Updated: Jul 2, 2014 Reviewedby Zalman S. Agus, MD ; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania Survival in esophageal cancer did not improve with the addition of ...
 MedPage Today3 weeks ago

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX ...
 CancerConnect.com1 month ago ASCO: Chemo Plus Avastin or Erbitux Boosts Colorectal Ca Survival  MedPage Today1 month ago Top 8 lessons learned at ASCO 2014  Orthopedics Today1 month ago ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?  Benzinga.com1 month ago

CRYSTAL analysis shows clinical benefit of Erbitux in RAS wild-type mCRC patients

Merck Serono, the biopharmaceutical division of Merck, has announced new biomarker findings from a retrospective analysis of the completed Phase III study CRYSTAL that compared Erbitux® (cetuximab) plus FOLFIRI with FOLFIRI alone. The analysis ...
 Medical News Today2 months ago Merck Announces New Retrospective Analysis Shows Significant Clinical Benefit in Overall Survival for Metastatic Colorectal Cancer Patients with RAS Wild-Type Tumors Receiving Erbitux plus FOLFIRI  Korea IT Times2 months ago
[x]  
RTTNews.com

Bristol-Myers Posts Lower Profit, Revenue -- Update

By Joshua Jamerson Bristol-Myers Squibb Co. reported declines in second-quarter earnings and revenue as the drug maker continues to restructure its operations. Results, though, surpassed analyst expectations, helped by strong sales of the ...
 Investors Hub17 hours ago Bristol-Myers Squibb's Q2 profit slips on higher R&D costs; Yervoy, Eliquis sales top estimates  FirstWord Pharma5 days ago Bristol-Myers Tops Profit Estimates Despite Sales Decline  RTTNews.com5 days ago BRISTOL MYERS SQUIBB : -Myers Posts Lower Profit, Revenue -- Update  4 Traders5 days ago
[x]  
Jutia Group

Company Update (NYSE:BMY): European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

[Business Wire] Bristol-Myers Squibb Company and Pfizer Inc. today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. Read more on this. ...
 Jutia Group21 hours ago Bristol Myers-Squibb 2nd-qtr sales dip 4% but still better than expected  Pharma Letter5 days ago Bristol-Myers reaffirms guidance after Q2 results  Seeking Alpha5 days ago Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results  Jutia Group5 days ago
[x]  

The Zacks Analyst Blog Highlights: Starbucks, Dunkin' Brands, Bristol-Myers Squibb, AstraZeneca and …

For Immediate Release Chicago, IL July 25, 2014 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
 Yahoo! Finance4 days ago The Zacks Analyst Blog Highlights:Starbucks, Dunkin' Brands, Bristol-Myers Squibb, AstraZeneca and Pfizer  Street Sweeper4 days ago THE ZACKS ANALYST BLOG HIGHLIGHTS : Starbucks, Dunkin' Brands, Bristol-Myers Squibb, AstraZeneca and Pfizer  4 Traders4 days ago
[x]  

Merck Backs Commitment To Future Investments In Chinese Market - Quick Facts

German drugmaker Merck (MKGAY.PK) reaffirmed its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy. This week, Merck's Executive Board met in Shanghai, a month before the ...
 RTTNews.com1 week ago MERCK KGAA : Strengthens Commitment to Chinese Growth Market  4 Traders1 week ago Merck Strengthens Commitment to Chinese Growth Market  Bionity.com5 days ago Merck Committed to Companion Diagnostics  Medical Design Technology2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less